Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06928844
Recruiting Not applicable

Role of Low Dose Injectable Progesterone in Triggering Ovulation

NCT06928844 · tracked via the Priya Life Science Egypt tracker
Sponsor
The General Authority for Teaching Hospitals and Institutes
Phase
Not applicable
Started
2025-04-15
Last updated
2025-04-16

Condition(s) studied

Low DoseProgesteroneTriggering Ovulation

Investigational drug(s) / intervention(s)

Progesterone →Placebo

Progesterone: Women will receive low dose progesterone 5 mg intramuscularly as a study group. (Letrozole 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).

Placebo: Women will receive placebo as a control group. (Placebo 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).

Study summary

The aim of this study is to evaluate the role of low dose injectable progesterone in triggering ovulation.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 20 to 35 years. * Infertile women. * Basal follicle-stimulating hormone (FSH) level \<10 mIU/ml. Exclusion Criteria: * Poor ovarian reserve. * Immunological disease. * Endometriosis. * Uterine abnormality. * Body mass index (BMI) \>30 kg/m2. * Endometrial thickness \<8 or \>12 mm on the day of triggering.

Primary outcome measure(s)

  • Incidence of ovulation rates — 10-12 days of the menstrual cycle
    Incidence of ovulation rates will be recorded.

Trial sites (1)

FacilityCityRegionStatus
Teaching Hospitals and Institutes Cairo Egypt Recruiting

More The General Authority for Teaching Hospitals and Institutes trials in Egypt

Autologous Serum Eye Drops in Dry Eye Syndrome Recruiting
Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction Recruiting
Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema Recruiting
Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases Recruiting
Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Casting Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06928844 on ClinicalTrials.gov ↗ ← All trials in Egypt